Pemazyre Gains New Indication for Myeloid/Lymphoid Neoplasms

The FDA granted a new indication for pemigatinib (Pemazyre, Incyte) to treat adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.


Pemigatinib is a selective fibroblast growth factor receptor inhibitor. The medication’s new approval is based on results from the multicenter, open-label, single-arm FIGHT-203 phase 2 clinical trial. The trial included 28 patients with relapsed or refractory MLNs who had a median